Motoneurone Disease Stroke Peripheral Neuropathy Multiple Sclerosis
Drug Platform Publications Collaborations
Our Mission Management Team Advisory Boards


CuroNZ News

After the recent release of the ASX statement by Calzada Ltd, Dr Frank Sieg, Cheif Scientific Officer of CuroNZ Ltd commented:

“CuroNZ Ltd is very pleased to have now secured a clear pathway for the commercialisation of the Neural Regeneration Peptide (NRP)-related technology. With the NRP portfolio now completely owned by CuroNZ, a smoother pathway for investment can be achieved  to progress the NRP development stage, closer to the initiation of human trials for devastating conditions like progressive Multiple Sclerosis and ALS.”

Click here for complete ASX announcement

Benefits of investing in CuroNZInternational Patent Claims

  • CuroNZ has an international patent portfolio of  patent claims directed at  neural regeneration and protection regarding the central nervous system
  • Supporting preclinical results showing neural regeneration and protection in relation to the central nervous system
  • $3.5 Million already invested in the development of these compounds
  • Lead compound in mid to late phase of preclinical development
  • Disease targets with promising results include several CNS diseases: motor neurone disease, multiple sclerosis, stroke and peripheral neuropathy
  • Our drug for motor neurone disease likely to  qualify for Orphan Drug status with the FDA
  • Orphan Drug status would enable clinical trials to be faster and more cost effective, as well as other benefits such as 7 year market exclusivity
  • Strong management team with neuroscience and IP experts
Contact us today to get more information on this exciting biotechnology venture.